作　　者： ;

机构地区： 广州医科大学

出　　处： 《中国实用内科杂志》 2019年第5期437-439,共3页

摘　　要： 2018年由广州呼吸健康研究院牵头,联合国内外多学科专家制定了我国首个嗜酸性肉芽肿性多血管炎诊治规范专家共识(简称2018共识),2018共识首次提出局限型嗜酸性肉芽肿性多血管炎(EGPA)概念,为EGPA的早期诊治提供依据。根据受累器官不同,2018共识首次提出局限型EGPA概念,为EGPA的早期诊断及治疗提供依据。EGPA患者的预后与最初治疗方案相关。EGPA的治疗取决于疾病的严重程度、受累的器官、病情是否活动等因素。总体治疗方案分为诱导缓解和维持治疗2个阶段。诱导缓解治疗方案主要包括激素和(或)免疫抑制剂(如环磷酰胺);病情达到缓解后,维持治疗推荐使用硫唑嘌呤或甲氨蝶呤,2015年全球EGPA诊治专家共识推荐的治疗时间为疾病达到缓解后至少24个月。2018共识结合当今国际最新进展,介绍了生物靶向治疗药物在EGPA的应用。 According to the different organs involved in patients, the concept of localized Eosinophilic granulomatous polyvasculitis(EGPA) was first proposed by consensus in 2018, which provides a basis for the early diagnosis and treatment of EGPA. The prognosis of patients with EGPA is related to the initial treatment. The treatment of EGPA depends on the severity of the disease, the organs involved and whether the disease is active or not. The overall treatment plan is divided into two stages: induction remission and maintenance therapy. Induced remission therapy mainly includes hormones and/or immunosuppressive agents(e.g. cyclophosphamide). After remission, azathioprine or methotrexate is recommended for maintenance therapy. In 2015, the global consensus of EGPA diagnostic and therapeutic experts recommended that the duration of treatment should be at least 24 months after remission. In combination with the latest international progress, the first Expert Consensus on Diagnosis and Treatment of EGPA in China 2018 consensus introduced the application of Bio-Targeting drugs in EGPA.

关 键 词： 嗜酸性肉芽肿性多血管炎 激素 免疫抑制剂

领　　域： []